Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Rapid Response Innovation Awards, 2014
    Screening Assays for Restored Protein Trafficking

    Study Rationale:
    Protein trafficking is the process by which proteins are transported from where they’re made to where they’re needed inside cells. Defects in trafficking cause proteins to accumulate...

  • Rapid Response Innovation Awards, 2014
    Alpha-synuclein Knock-down Peptides for Neuroprotection and Reversal of Pathology in a Model of Parkinson’s Disease

    Study Rationale:
    Protein misfolding and aggregation is likely to be a central mechanism in the neurodegenerative changes seen in Parkinson’s disease (PD). The Canadian partner in this project has...

  • Research Grant, 2014
    Imaging Neuroinflammation in LRRK2 Models of Parkinson’s Disease

    Objective/Rationale:
    The mechanisms for the initiation and progression of the loss of dopamine (DA) neurons in Parkinson’s disease (PD) are still largely unknown. Increasing evidence indicates that...

  • LRRK2 LEAPS, 2014
    Targeting Retromer Dysfunction: A Convergent Mechanism in Familial and Sporadic Parkinson’s Disease

    Study Rationale:                   
    Our goal is to understand how mutations in the gene LRRK2 can drive Parkinson’s disease (PD) risk. Our previous studies of neurons with mutant LRRK2 kinase have...

  • LRRK2 Challenge, 2014
    Inhibition of PKA as a Mechanism to Reverse LRRK2 Mutation-induced Parkinson's Disease

    Study Rationale:
    Unraveling the role of LRRK2 mutations in disease remains a critical question in Parkinson’s research. The high expression of LRRK2 protein in part of the brain called the striatum...

  • Target Validation, 2014
    5-alpha-reductase Inhibition for the Treatment of Levodopa-induced Dyskinesia

    Study Rationale:
    Although the cause of levodopa-induced dyskinesia is still unclear, these motor complications appear to be due to abnormal dopamine transmission in the brain. Compelling evidence has...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.